Search results for "blood coagulation"

showing 10 items of 154 documents

Myopathic form of arthrogryposis and microcirculation lesion.

1989

A microvascular lesion characterized by extensive platelet aggregation, thrombosis, vascular damage with hemorrhages was found in the muscle of a 2-month-old boy with a myopathic form of the arthrogryposis syndrome. The lesion morphologically resembled the vascular leakage seen in immunologically mediated tissue injury. A degradative effect of proteases released during platelet and neutrophil aggregation on the muscle and joints is suggested.

ArthrogryposisArthrogryposisMalePathologymedicine.medical_specialtyVascular diseasebusiness.industryMusclesInfantAnatomyBlood Coagulation Disordersmedicine.diseaseThrombosisPathophysiologyMicrocirculationLesionNeurologyMuscular DiseasesmedicineHumansPlateletNeurology (clinical)medicine.symptombusinessNeutrophil aggregationJournal of the neurological sciences
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response

2000

Objectives: The aim of the present study was to evaluate the effects of pravastatin treatment on lipid, inflammation, and coagulation parameters in patients suffering from myocardial infarction with or without carotid atherosclerotic lesions (groups 1 and 2, respectively). Methods: In the first phase of the study, a cross-sectional comparison of lipid, inflammation, and coagulation parameters was performed between the patients and the control group (group 3). Highly significant differences in these parameters were observed, especially in group 1. In the second phase of the study, we assessed the effects of a persistent reduction in cholesterol synthesis induced by increasing doses of pravas…

Blood GlucoseMalemedicine.medical_specialtyMyocardial InfarctionInflammationCoronary Artery DiseaseFibrinogenchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansPharmacology (medical)PravastatinInflammationPharmacologyDose-Response Relationship DrugFactor VIIbusiness.industryCholesterolpravastatin inflammatory responseGeneral MedicineMiddle AgedBlood Coagulation FactorsCholesterolCross-Sectional StudiesEndocrinologyCoagulationchemistryCase-Control StudiesHemostasisFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessPravastatinmedicine.drugLipoproteinEuropean Journal of Clinical Pharmacology
researchProduct

Haemostasis in chronic kidney disease

2013

The coagulation system has gained much interest again as new anticoagulatory substances have been introduced into clinical practice. Especially patients with renal failure are likely candidates for such a therapy as they often experience significant comorbidity including cardiovascular diseases that require anticoagulation. Patients with renal failure on new anticoagulants have experienced excessive bleeding which can be related to a changed pharmacokinetic profile of the compounds. However, the coagulation system itself, even without any interference with coagulation modifying drugs, is already profoundly changed during renal failure. Coagulation disorders with either episodes of severe bl…

Blood PlateletsExcessive Bleedingmedicine.medical_specialtymedicine.medical_treatmentHemorrhageThrombophiliaInternal medicinemedicineHumansRenal InsufficiencyRenal Insufficiency ChronicHemostatic functionBlood CoagulationCoagulation DisorderHemostasisTransplantationbusiness.industryAnticoagulantsThrombosisBlood Coagulation Disordersmedicine.diseaseThrombosisSurgeryOxidative StressCoagulationNephrologyAntibodies AntiphospholipidCardiologyEndothelium VascularHemodialysisbusinessKidney diseaseNephrology Dialysis Transplantation
researchProduct

Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension

2017

Multicellular interactions of platelets, leukocytes, and the blood vessel wall support coagulation and precipitate arterial and venous thrombosis. High levels of angiotensin II cause arterial hypertension by a complex vascular inflammatory pathway that requires leukocyte recruitment and reactive oxygen species production and is followed by vascular dysfunction. We delineate a previously undescribed, proinflammatory coagulation-vascular circuit that is a major regulator of vascular tone, blood pressure, and endothelial function. In mice with angiotensin II-induced hypertension, tissue factor was up-regulated, as was thrombin-dependent endothelial cell vascular cellular adhesion molecule 1 ex…

Blood PlateletsMale0301 basic medicinemedicine.medical_specialtyMacrophage-1 AntigenVascular Cell Adhesion Molecule-1Blood Pressure030204 cardiovascular system & hematologyThromboplastinMice03 medical and health sciencesTissue factor0302 clinical medicineThrombinInternal medicinemedicineAnimalsHumansPlateletRats WistarEndothelial dysfunctionBlood CoagulationFactor XIAgedMice Knockoutbusiness.industryAngiotensin IIThrombinGeneral MedicineMiddle AgedOligonucleotides Antisensemedicine.diseaseAngiotensin IIMice Inbred C57BL030104 developmental biologyEndocrinologyBlood pressuremedicine.anatomical_structurePlatelet Glycoprotein GPIb-IX ComplexPathophysiology of hypertensionHypertensionFemalebusinessmedicine.drugBlood vesselScience Translational Medicine
researchProduct

Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.

2017

In patients with stable coronary artery disease, clinical outcomes are predominantly characterized by the consequences of atherosclerosis on the myocardium, but also by complications of atherosclerosis, notably recurrent acute coronary syndrome or stroke. Secondary prevention therapy is therefore key in this patient population. Intensification of secondary prevention therapy is possible, at the price of a therapeutic risk or a high cost, therefore justifying careful selection of patients with a high residual risk and low therapeutic risk. Two lines of therapy can be intensified, independently of each other, namely anti-thrombotics and lipid-lowering agents. Intensification of anti-thromboti…

Blood Plateletsmedicine.medical_specialtyAcute coronary syndromeStatinEpidemiologymedicine.drug_classCoronary Artery Disease030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineEzetimibeFibrinolytic AgentsRecurrenceRisk FactorsInternal medicineDiabetes mellitusmedicineSecondary PreventionHumans030212 general & internal medicineMyocardial infarctionStrokeBlood CoagulationDyslipidemiasHypolipidemic Agentsbusiness.industryPatient Selectionmedicine.diseaseLipidsResidual riskTreatment OutcomeDisease ProgressionCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugEuropean journal of preventive cardiology
researchProduct

Potential of Multidimensional, Large-scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach towards Precision Medicine in T…

2019

Cardiovascular and especially thrombotic diseases remain a major cause of morbidity and mortality worldwide. In past years, significant improvements in understanding disease processes, risk assessment, and prediction of clinical outcome in the field of thrombosis and haemostasis have been made by using large-scale biodatabases. These important research resources enable a comprehensive research approach by integrating clinical, environmental, genomic, and molecular information. Cutting edge, high throughput technologies open new data dimensions for clinical large-scale investigations. Joining multiple information levels from several pathophysiological pathways in contrast to a single marker …

Blood Plateletsmedicine.medical_specialtyDatabases Factualbusiness.industryThrombosisHematologyDisease030204 cardiovascular system & hematologyDisease pathogenesisPrecision medicine03 medical and health sciences0302 clinical medicineCoagulationmedicineHumansPlateletThrombotic diseasePrecision MedicineRisk assessmentIntensive care medicinebusinessBlood CoagulationVenous thromboembolismBiomarkers030215 immunologyHämostaseologie
researchProduct

Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma

2005

Thrombosis is the most frequent complication and the second cause of death in patients with malignant disease. Primary central nervous system non-Hodgkin's lymphoma represents a rare pathology. Resistance to APC is usually linked to a factor V (FV) gene mutation changing an Arg 506 to a Gln in the APC cleavage site.In our study, we aimed at investigating the presence of activated protein C resistance (APC-r) and other markers of hypercoagulability in 25 selected patients with a diagnosis of primitive cerebral lymphoma who had suffered from an ischemic episode of TIA and/or stroke.25 selected patients with a diagnosis of primitive cerebral lymphoma and 50 healthy subjects acted as control gr…

Brain NeoplasmsLymphoma Non-HodgkinFactor VPeptide FragmentsBrain NeoplasmStrokePhenotypePeptide FragmentIschemic Attack TransientCase-Control StudiesMutationPlasminogen Activator Inhibitor 1HumansProthrombinCase-Control StudieBlood CoagulationBiomarkersHumanActivated Protein C Resistance
researchProduct

Elevated levels of lipoprotein (a) in patients suffering from myocardial infarction with carotid atherosclerotic lesions.

1999

The aim of the present study was to evaluate metabolic, coagulation and fibrinolytic parameters in 45 patients [31 men, 14 women, aged 56.5 +/- 3.5 years (mean +/- SD)] who had suffered myocardial infarction more than 6 months earlier, with or without carotid atherosclerotic lesions. After the extracranial carotid arteries had been evaluated using a B-mode Duplex scanning system, patients were subdivided into two groups: group 1 (n = 20) with carotid plaques or measurable intima-media thickness; and group 2 (n = 25) without carotid plaques or measurable intima-media thickness. Twenty-two age- and sex-matched subjects were recruited as controls (group 3). Groups 1 and 2 displayed significant…

Carotid Artery DiseasesMalemedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentLipoproteinsMyocardial InfarctionFibrinogenBody Mass IndexRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionBlood CoagulationTriglyceridesbiologybusiness.industryFibrinolysisHematologyGeneral MedicineLipoprotein(a)Middle Agedmedicine.diseaseEndocrinologyApolipoproteinsCholesterolbiology.proteinCardiologyApolipoprotein A1FemalebusinessPlasminogen activatorProtein CBiomarkersLipoproteinmedicine.drugLipoprotein(a)Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Procoagulant activity during viral infections.

2017

The abundance of evidence suggest that inflammation of immune and non-immune cells may lead to an imbalance of the pro- and anti-coagulant state during viral infections. During systemic infections, the endothelium plays a critical role in regulating hemostasis, and severe imbalances of endothelial function and activation can contribute to organ failure. Viral infections may elevate plasma levels of procoagulant markers such as TAT and D-dimer TF-positive MPs as well as von Willebrand factor (vWF). Although multiple clinical studies are showing the association of viral infection and increased prothrombotic risk, the pathological mechanisms have not been fully identified for most viral infect…

Cell typeEndotheliumInflammation030204 cardiovascular system & hematologyThromboplastin03 medical and health sciences0302 clinical medicineImmune systemVon Willebrand factorvon Willebrand FactormedicineAnimalsHumansReceptorBlood CoagulationHemostasisbiologybusiness.industryToll-Like ReceptorsBlood Coagulation Factorsmedicine.anatomical_structureCoagulationVirus DiseasesHemostasisImmunologybiology.proteinmedicine.symptombusiness030217 neurology & neurosurgeryBiomarkersFrontiers in bioscience (Landmark edition)
researchProduct